

# Prevention & Treatment of Hepatitis and Chronic Liver Disease

**Atlanta, GA September 7, 2024**

<b>Conference Location</b>	<b>AC Hotel Buckhead at Phipps Plaza</b> 3600 Wieuca Rd, NE Atlanta, GA 30326 (471) 231-3030	<a href="https://www.marriott.com/en-us/hotels/atlac-ac-hotel-atlanta-buckhead-at-hippys-plaza/overview/?scid=f2ae0541-1279-4f24-b197-a979c79310b0">https://www.marriott.com/en-us/hotels/atlac-ac-hotel-atlanta-buckhead-at-hippys-plaza/overview/?scid=f2ae0541-1279-4f24-b197-a979c79310b0</a>
<b>Parking and Guest Rooms at the Conference</b>	Self-Parking for day guests in complementary  A <b>special guest room rate of \$179</b> is available for Friday evening, September 6 <sup>th</sup> Please book your room by <b>August 15</b> by contacting the hotel	
<b>Driving Directions</b>	The hotel is the heart of the Buckhead shopping area – adjacent to Phipps Plaza and at the corner of Wieuca Road and Peachtree Road, NE.	
<b>Seminar Agenda and Syllabus Information</b>	Registration begins at <b>7:30 a.m.</b> outside the Phipps-Lennox rooms  <b>The Hepatitis and Chronic Liver Disease seminar is a paperless program.</b> The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the <i>App</i> will be provided. Wi-Fi will be available without charge.	

<b>Pre-Program Activities</b>	<b>Pre-Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min <b>Pre-Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
<b>7:30 am</b>	<i>Registration and View Exhibits</i>
<b>8:00 am</b>	<b>Opening Comments and Pre-Test</b>
<b>8:20 am</b>	<b>Advances in the Screening and Treatment of HCV</b> <ul style="list-style-type: none"> <li>• Updates on diagnostic approaches</li> <li>• Caring for At-risk populations – homeless, PWID, the incarcerated</li> <li>• Novel FDA Approved Direct Acting Anti-virals</li> <li>• Clinical Cases and Discussion</li> </ul>
<b>9:10 am</b>	<b>Hepatitis B: Epidemiology, History, Testing and Treatment</b> <ul style="list-style-type: none"> <li>• The epidemiology of the Hepatitis B infection</li> <li>• Efficacies and opportunities in HBV testing and vaccination</li> <li>• The efficacy of HBV Vaccination and Anti-viral therapies of HBV</li> <li>• HBV Re-activation and the Latest studies from EASL and AASLD</li> </ul>
<b>9:40 am</b>	<b>Delta Hepatitis and Hepatitis E Update</b> <ul style="list-style-type: none"> <li>• Global and US perspective on the growth of Delta Hepatitis</li> <li>• Lonafarnib and Bulevirtide of HDV: Benefits and potential hazards</li> <li>• Testing and surveillance approaches</li> <li>• Real world outcome studies on HDV and HEV</li> </ul>
<b>10:15 am</b>	<i>Industry Presentation, Break and View exhibits</i>
<b>11:00 am</b>	<b>End Stage Liver Disease: Recap and Clinical Cases</b> <ul style="list-style-type: none"> <li>• A review of Pre-course lecture on end-stage liver disease</li> <li>• Complications of cirrhosis</li> <li>• Liver transplant in the era of DAA’s Clinical cases to illustrate HE. HRS and/or Thrombocytopenia</li> </ul>
<b>11:30 am</b>	<b>Hepatocellular Carcinoma(HCC) - Screening and Disease Progression</b> <ul style="list-style-type: none"> <li>• Screening diagnostic serum assays and imaging tests</li> <li>• Treatment and management options: Ablation, TACE and Surgery</li> </ul>

	<ul style="list-style-type: none"> <li>• New studies showing cost effectiveness of surveillance post SVR</li> <li>• PRIUS Study (MRI vs US) Abbreviated MRI</li> <li>• 2023 AASLD screening guidance for liver cancer and comments on biopsy for HCC</li> </ul>
12:00 pm	<b>Hepatocellular Carcinoma: A case-based approach to New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>• Promising 1<sup>st</sup> and 2<sup>nd</sup> line therapies for liver cancer</li> <li>• New data on the benefit of downstaging</li> <li>• C chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC</li> <li>• Checkpoint inhibitors and VEGE inhibitors</li> </ul>
12:30 pm	<b>Luncheon and Product Information Session</b>
1:10 pm	<b>Dessert and View Exhibits</b>
1:20 pm	<b>Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis</b> <ul style="list-style-type: none"> <li>• Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>• Causes and Markers of PBC</li> <li>• Coping with the clinical features of PBC</li> <li>• Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> <li>• Highlights of the ELATIVE study on elafibanor and the RESPONSE study on seladelpar</li> </ul>
2:05 pm	<b>Alcohol Associated Liver Disease</b> <ul style="list-style-type: none"> <li>• The growing prevalence of alcohol over-consumption and its impact on liver health</li> <li>• Alcohol consumption and malnutrition</li> <li>• Warning signs and intervention in alcohol-associated hepatitis</li> <li>• Promising therapeutic agents for AAH</li> </ul>
2:35 pm	<b>Break &amp; View Exhibits</b>
2:50 pm	<b>Steatotic Liver Disease: The new healthcare epidemic</b> <ul style="list-style-type: none"> <li>• New naming conventions for fatty liver disease: MASLD and MASH– what and why?</li> <li>• Epidemiology, Demographics and Diagnosis</li> <li>• Scoring, Staging and Management of Metabolic Liver Disease</li> <li>• The ‘unhealthy’ rise in MASLD in the US population and What can be done</li> <li>• Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> </ul>
3:25 pm	<b>MASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>• Current therapies for NASH including Updates from AASLD and EASL</li> <li>• Lifestyle changes as a therapy</li> <li>• Drugs in clinical development for NASH – Semaglutide and Resmitemon</li> <li>• MASH Diagnosis and Treatment case</li> </ul>
4:05 pm	<b>Closing Comments, Post-test and Wrap-Up</b> Program adjourns at 4:15 pm
Post-program activities	<b>Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome</b> 30 minutes <b>Lecture 4 - Overcoming barriers to liver health in special populations</b> - 30 minutes. <b>Lecture 5 – AASLD Update – Highlights of the 2023 Liver Meeting</b> – 30 minutes

#### Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

#### Attendance Policies

##### Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

##### Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

---

**Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---

**CME  
Information**

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)<sup>TM</sup>**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1383 The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)<sup>TM</sup> organizations accredited by ACCME.

---

**ANAND S. SHAH MD**

*Dr. Anand S. Shah serves as the Director of Hepatology at the Joseph Maxwell Cleland Atlanta VA Medical Center since 2020. He received his B.A. from Indiana University, Bloomington, and completed his medical degree from Indiana University School of Medicine. He completed his internship and residency at Emory School of Medicine and a Fellowship in Gastroenterology and Hepatology at State University of New York at Downstate Medical Center in Brooklyn, NY.*

*Dr. Shah is an Assistant Professor of Medicine at the Emory School of Medicine. His clinical research focuses on quality improvement in chronic liver disease, cirrhosis, and Hepatocellular Carcinoma (HCC). He has given*

*lectures nationally on health maintenance and prevention in patients living with chronic liver disease and cirrhosis. He is a member of the National VA Hepatology Field Advisory committee for HCC and has published several articles on HCC surveillance and treatment.*

**Your Seminar  
Faculty****LANCE STEIN, MD**

*Dr. Lance Stein is the Medical Director of Piedmont Atlanta Hospital's Hepatology and Liver Transplant program, in this role since 2021 and has been at Piedmont Transplant since 2010. He has an academic appointment as a Clinical Assistant Professor of Medicine at Mercer University School of Medicine. He graduated from Temple University School of Medicine, then completed residency in internal medicine at Emory University School of Medicine, followed by a gastroenterology fellowship at the University of California, San Diego then a fellowship in Advanced/Transplant Hepatology at both Columbia and Cornell-New York Presbyterian Hospitals.*

*His clinical and research interests are in the management of the complications of liver cirrhosis including portal hypertension with a focus on acute on chronic liver failure, metabolic associated liver steatotic dysfunction (MASH/MAFLD), cholestatic liver diseases, and alcohol related liver disease.*

---